| First Author | Panaro BL | Year | 2017 |
| Journal | Diabetes | Volume | 66 |
| Issue | 6 | Pages | 1626-1635 |
| PubMed ID | 28254842 | Mgi Jnum | J:246169 |
| Mgi Id | MGI:5922815 | Doi | 10.2337/db17-0017 |
| Citation | Panaro BL, et al. (2017) beta-Cell Inactivation of Gpr119 Unmasks Incretin Dependence of GPR119-Mediated Glucoregulation. Diabetes 66(6):1626-1635 |
| abstractText | GPR119 was originally identified as an orphan beta-cell receptor; however, subsequent studies demonstrated that GPR119 also regulates beta-cell function indirectly through incretin hormone secretion. We assessed the importance of GPR119 for beta-cell function in Gpr119-/- mice and in newly generated Gpr119betacell-/- mice. Gpr119-/- mice displayed normal body weight and glucose tolerance on a regular chow (RC) diet. After high-fat feeding, Gpr119-/- mice exhibited reduced fat mass, decreased levels of circulating adipokines, improved insulin sensitivity, and better glucose tolerance. Unexpectedly, oral and intraperitoneal glucose tolerance and the insulin response to glycemic challenge were not perturbed in Gpr119betacell-/- mice on RC and high-fat diets. Moreover, islets from Gpr119-/- and Gpr119betacell-/- mice exhibited normal insulin responses to glucose and beta-cell secretagogues. Furthermore, the selective GPR119 agonist AR231453 failed to directly enhance insulin secretion from perifused islets. In contrast, AR231453 increased plasma glucagon-like peptide 1 (GLP-1) and insulin levels and improved glucose tolerance in wild-type and Gpr119betacell-/- mice. These findings demonstrate that beta-cell GPR119 expression is dispensable for the physiological control of insulin secretion and the pharmacological response to GPR119 agonism, findings that may inform the lack of robust efficacy in clinical programs assessing GPR119 agonists for the therapy of type 2 diabetes. |
